KEGG DRUG: Reteplase

DRUG: Reteplase

Entry

D05721                      Drug

Name

Reteplase (USAN/INN);
Retevase (TN)

Formula

C1736H2653N499O522S22

Exact mass

39546.0247

Mol weight

39571.15

Sequence

SYQGNSDCYF GNGSAYRGTH SLTESGASCL PWNSMILIGK VYTAQNPSAQ ALGLGKHNYC
RNPDGDAKPW CHVLKNRRLT WEYCDVPSCS TCGLRQYSQP QFRIKGGLFA DIASHPWQAA
IFAKHRRSPG ERFLCGGILI SSCWILSAAH CFQERFPPHH LTVILGRTYR VVPGEEEQKF
EVEKYIVHKE FDDDTYDNDI ALLQLKSDSS RCAQESSVVR TVCLPPADLQ LPDWTECELS
GYGKHEALSP FYSERLKEAH VRLYPSSRCT SQHLLNRTVT DNMLCAGDTR SGGPQANLHD
ACQGDSGGPL VCLNDGRMTL VGIISWGLGC GQKDVPGVYT KVTNYLDWIR DNMRP
(Disulfide bridge: 8-89, 29-71, 60-84, 92-223, 135-151, 143-212, 273-312, 269-285, 302-330)

Type

Peptide

Class

Blood modifier agent
DG01950  Antithrombotic agent
  DG01707  Fibrinolytic
   DG01664  Tissue plasminogen activator (t-PA)

Remark

ATC code:

B01AD07

Efficacy

Thrombolytic, Tissue plasminogen activator (t-PA)

Disease

Myocardial infarction [DS:H01730]

Comment

tissue plasminogen activator (t-PA) [HSA:5327] [KO:K01343] [EC:3.4.21.68]
Myocardial infarction therapy

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AD Enzymes
     B01AD07 Reteplase
      D05721  Reteplase (USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
  DG01950  Antithrombotic agent
   DG01707  Fibrinolytic
    DG01664  Tissue plasminogen activator (t-PA)
     D05721  Reteplase
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D05721

Other DBs

CAS:	133652-38-7

PubChem:

47207382

» Japanese version » Back

All links

Ontology (3)   
   KEGG BRITE (3)   
Disease (1)   
   KEGG DISEASE (1)   
Drug (1)   
   KEGG DGROUP (1)   
Chemical substance (1)   
   PubChem (1)   
All databases (6)   

Download RDF

DBGET integrated database retrieval system